MA57226B1 - Méthodes de traitement d'une splénomégalie - Google Patents
Méthodes de traitement d'une splénomégalieInfo
- Publication number
- MA57226B1 MA57226B1 MA57226A MA57226A MA57226B1 MA 57226 B1 MA57226 B1 MA 57226B1 MA 57226 A MA57226 A MA 57226A MA 57226 A MA57226 A MA 57226A MA 57226 B1 MA57226 B1 MA 57226B1
- Authority
- MA
- Morocco
- Prior art keywords
- splenomegaly
- methods
- treatment
- relates
- therapeutic methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Saccharide Compounds (AREA)
- Processing Of Solid Wastes (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
L'invention concerne des méthodes thérapeutiques et des compositions pharmaceutiques pour traiter une splénomégalie chez un sujet humain. Dans certains modes de réalisation, l'invention concerne des méthodes thérapeutiques de traitement d'une splénomégalie à l'aide d'un inhibiteur de btk.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062958632P | 2020-01-08 | 2020-01-08 | |
PCT/US2021/012696 WO2021142257A1 (fr) | 2020-01-08 | 2021-01-08 | Méthodes de traitement d'une splénomégalie |
Publications (2)
Publication Number | Publication Date |
---|---|
MA57226A1 MA57226A1 (fr) | 2023-02-28 |
MA57226B1 true MA57226B1 (fr) | 2023-06-28 |
Family
ID=76788747
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA57226A MA57226B1 (fr) | 2020-01-08 | 2021-01-08 | Méthodes de traitement d'une splénomégalie |
MA63848A MA63848A1 (fr) | 2020-01-08 | 2021-01-08 | Méthodes de traitement d'une splénomégalie |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA63848A MA63848A1 (fr) | 2020-01-08 | 2021-01-08 | Méthodes de traitement d'une splénomégalie |
Country Status (14)
Country | Link |
---|---|
EP (2) | EP3980069A4 (fr) |
JP (1) | JP2023509968A (fr) |
KR (1) | KR20220130151A (fr) |
CN (1) | CN114423457A (fr) |
AU (1) | AU2021205484A1 (fr) |
BR (1) | BR112022013646A2 (fr) |
CA (1) | CA3164063A1 (fr) |
CO (1) | CO2022010592A2 (fr) |
CR (1) | CR20220374A (fr) |
IL (1) | IL294582A (fr) |
JO (1) | JOP20220168A1 (fr) |
MA (2) | MA57226B1 (fr) |
MX (1) | MX2022008490A (fr) |
WO (1) | WO2021142257A1 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL294582A (en) * | 2020-01-08 | 2022-09-01 | Telios Pharma Inc | Methods for treating an enlarged spleen |
US20240024314A1 (en) | 2020-01-08 | 2024-01-25 | Telios Pharma, Inc. | Methods of Treating Splenomegaly |
WO2023071973A1 (fr) * | 2021-10-26 | 2023-05-04 | Shenzhen Targetrx, Inc. | Composé bicyclique fusionné pour inhiber l'activité de la tyrosine kinase |
WO2024041614A1 (fr) * | 2022-08-25 | 2024-02-29 | Beigene Switzerland Gmbh | Formes solides comprenant du (s)-7-(1-acryloylpipéridin-4-yl)-2-(4-phénoxyphényl)-4,5,6, 7-tétrahydropyrazolo[1, 5-a]pyrimidine-3-carboxamide, et de l'acide oxalique, compositions et procédés d'utilisation associés |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015057992A1 (fr) * | 2013-10-16 | 2015-04-23 | Izumi Raquel | Inhibiteurs btk pour la mobilisation hématopoïétique |
HUE056329T2 (hu) * | 2014-08-11 | 2022-02-28 | Acerta Pharma Bv | BTK-inhibitor és BCL-2-inhibitor terápiás kombinációi |
US9708348B2 (en) * | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
WO2019243223A1 (fr) * | 2018-06-19 | 2019-12-26 | Merck Patent Gmbh | Nouvelles formes cristallines de 1-(4-{[6-amino-5-(4-phénoxy-phényle)pyrimidin-4-ylamino]-méthyl}-4-fluoro-pipéridin-1-yl)-propénone, formes salines de celle-ci, et procédés d'obtention |
TW202128156A (zh) * | 2019-11-14 | 2021-08-01 | 美商夸格智財控股有限公司 | 用於癌症治療之btk抑制劑及mdm2抑制劑之組合 |
IL294582A (en) * | 2020-01-08 | 2022-09-01 | Telios Pharma Inc | Methods for treating an enlarged spleen |
-
2021
- 2021-01-08 IL IL294582A patent/IL294582A/en unknown
- 2021-01-08 WO PCT/US2021/012696 patent/WO2021142257A1/fr active Application Filing
- 2021-01-08 JP JP2022542216A patent/JP2023509968A/ja active Pending
- 2021-01-08 CN CN202180004918.1A patent/CN114423457A/zh active Pending
- 2021-01-08 MX MX2022008490A patent/MX2022008490A/es unknown
- 2021-01-08 JO JOP/2022/0168A patent/JOP20220168A1/ar unknown
- 2021-01-08 EP EP21738476.7A patent/EP3980069A4/fr active Pending
- 2021-01-08 CR CR20220374A patent/CR20220374A/es unknown
- 2021-01-08 EP EP22150344.4A patent/EP4000624A1/fr active Pending
- 2021-01-08 AU AU2021205484A patent/AU2021205484A1/en active Pending
- 2021-01-08 MA MA57226A patent/MA57226B1/fr unknown
- 2021-01-08 MA MA63848A patent/MA63848A1/fr unknown
- 2021-01-08 KR KR1020227027305A patent/KR20220130151A/ko unknown
- 2021-01-08 BR BR112022013646A patent/BR112022013646A2/pt unknown
- 2021-01-08 CA CA3164063A patent/CA3164063A1/fr active Pending
-
2022
- 2022-07-28 CO CONC2022/0010592A patent/CO2022010592A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CO2022010592A2 (es) | 2022-10-31 |
JP2023509968A (ja) | 2023-03-10 |
KR20220130151A (ko) | 2022-09-26 |
EP3980069A1 (fr) | 2022-04-13 |
IL294582A (en) | 2022-09-01 |
EP3980069A4 (fr) | 2022-08-17 |
WO2021142257A1 (fr) | 2021-07-15 |
MA63848A1 (fr) | 2024-04-30 |
AU2021205484A1 (en) | 2022-08-18 |
EP4000624A1 (fr) | 2022-05-25 |
CN114423457A (zh) | 2022-04-29 |
JOP20220168A1 (ar) | 2023-01-30 |
BR112022013646A2 (pt) | 2022-10-04 |
CR20220374A (es) | 2023-01-25 |
MA57226A1 (fr) | 2023-02-28 |
CA3164063A1 (fr) | 2021-07-15 |
MX2022008490A (es) | 2022-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA57226B1 (fr) | Méthodes de traitement d'une splénomégalie | |
MA51918A (fr) | Compositions et méthodes de traitement d'une hypoacousie non associée à l'âge chez un sujet humain | |
MA54227B1 (fr) | Méthodes de traitement de la fibrose kystique | |
DK1346041T3 (da) | Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom | |
MA37829A1 (fr) | Combinaisons pharmaceutiques comprenant un inhibiteur de b-raf, un inhibiteur d'egfr et facultativement un inhibiteur de pi3k alpha | |
MA44764A (fr) | Méthodes de traitement de patients présentant une hypercholestérolémie familiale | |
MA30413B1 (fr) | Nouvelles compositions pharmaceutiques faiblement dosees contenant du nimesulide, leur preparation et utilisation | |
MA40768B1 (fr) | Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue | |
MA29489B1 (fr) | Utilisation de tfpi dans le traitement d'infections bacteriennes aigues | |
EA202190308A1 (ru) | Применение пролекарств рилузола для лечения болезни альцгеймера | |
EA202190544A1 (ru) | Применение распадающихся в полости рта таблеток рилузола для лечения заболеваний | |
MA39447A1 (fr) | (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine | |
CY1105545T1 (el) | Θεραπεια στατινης για ενισχυση της διατηρησης νοητικης λειτουργιας | |
ATE499933T1 (de) | Verwendung von betain zur behandlung von claudicatio intermittens | |
MX2020007941A (es) | Metodo para prevenir o tratar enfermedad de alzheimer. | |
MA39448A1 (fr) | (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical | |
MA56607A1 (fr) | Méthodes de traitement de troubles dépressifs | |
EA202193190A1 (ru) | Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов | |
AU2020360413A8 (en) | Methods of treating conditions related to the S1P1 receptor | |
FR3097743B1 (fr) | Produit de combinaison pour aider au maintien des défenses naturelles de l’organisme | |
DE60131100D1 (de) | Verfahren zur behandlung bestimmter augenkrankheiten | |
MA53135B1 (fr) | Composés de c-mannoside utiles pour le traitement d'infections des voies urinaires | |
EA202092349A1 (ru) | Лактитол и пероральная лекарственная форма при неалкогольной жировой болезни печени | |
Kiełbasa et al. | Searching for the Holy Grail among ear drops | |
DE69619542D1 (de) | Bismut enthaltende zusammensetzungen zur verhütung und behandlung gastrointestinaler beschwerden |